IP Library › Granted Patent US 12,409,227
Granted Patent B2
US 12,409,227 · App. 18/619,502 · Granted Sep 9, 2025

Cochleates made with soy phosphatidylserine

Inventors: Raphael Mannino (Glen Gardner, NJ); Ruying Lu (New Providence, NJ)
Assignees: Rutgers, The State University of New Jersey; MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
A61K47/24A61K9/1274A61K9/1277A61K9/19A61K31/12A61K31/122A61K31/685A61K31/7036A61K31/7048A61K33/06A61K45/06A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,227
App. No.
18/619,502
Granted
Sep 9, 2025
Kind
B2
Abstract

Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.

Claims (24)

1. A method of treating a subject with a fungal infection comprising, administering to the subject a composition comprising a cochleate comprising (i) a soy-based phospholipid comprising about 40%-55% by weight soy phosphatidylserine, (ii) a multivalent cation, and (iii) an anti-fungal agent.

2. The method of claim 1 wherein the soy-based phospholipid comprises about 45%-55% by weight soy phosphatidylserine.

3. The method of claim 1 , wherein the soy-based phospholipid comprises about 40% by weight soy phosphatidylserine.

4. The method of claim 1 , wherein the soy-based phospholipid comprises about 45% by weight soy phosphatidylserine.

5. The method of claim 1 , wherein the soy-based phospholipid comprises about 50% by weight soy phosphatidylserine.

6. The method of claim 1 , wherein the soy-based phospholipid comprises about 55% by weight soy phosphatidylserine.

7. The method of claim 1 , wherein the antifungal agent is amphotericin B.

8. The method of claim 1 , wherein the multivalent cation is Ca++, Zn++, Ba++, or Mg++.

9. The method of claim 8 , wherein the multivalent cation is Ca++.

10. The method of claim 1 , wherein the soy-based phospholipid is a mixture comprising (i) soy phosphatidylserine and (ii) phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, or any combination thereof.

11. The method of claim 1 , wherein the soy-based phospholipid is a mixture comprising (i) soy phosphatidylserine and (ii) phosphatidylcholine, phosphatidylinositol, or phosphatidylglycerol.

12. The method of claim 11 , wherein the mixture comprises (i) soy phosphatidylserine and (ii) phosphatidylcholine.

13. The method of claim 1 , wherein the subject is immune compromised.

14. The method of claim 1 , wherein the composition is orally administered to the subject.

15. A method of treating a subject with a fungal infection comprising, administering to the subject a composition comprising a cochleate comprising (i) a soy-based phospholipid comprising a mixture comprising soy phosphatidylserine and phosphatidylcholine, (ii) a multivalent cation, and (iii) amphotericin B, wherein the soy-based phospholipid comprises about 40%-55% by weight soy phosphatidylserine.

16. The method of claim 15 wherein the soy-based phospholipid comprises about 45%-55% by weight soy phosphatidylserine.

17. The method of claim 15 , wherein the soy-based phospholipid comprises about 40% by weight soy phosphatidylserine.

18. The method of claim 15 , wherein the soy-based phospholipid comprises about 45% by weight soy phosphatidylserine.

19. The method of claim 15 , wherein the soy-based phospholipid comprises about 50% by weight soy phosphatidylserine.

20. The method of claim 15 , wherein the soy-based phospholipid comprises about 55% by weight soy phosphatidylserine.

21. The method of claim 15 , wherein the multivalent cation is Ca++, Zn++, Ba++, or Mg++.

22. The method of claim 21 , wherein the multivalent cation is Ca++.

23. The method of claim 15 , wherein the subject is immune compromised.

24. The method of claim 15 , wherein the composition is orally administered to the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2024
From: MANNINO, RAPHAEL
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 067005/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2024
From: LU, RUYING
To: COORDINATED PROGRAM DEVELOPMENT, LLC
Reel/Frame 067005/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2024
From: COORDINATED PROGRAM DEVELOPMENT, LLC
To: AQUARIUS BIOTECHNOLOGIES, INC.
Reel/Frame 067005/0841 →
CHANGE OF NAME Recorded Apr 4, 2024
From: AQUARIUS BIOTECHNOLOGIES, INC.
To: MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Reel/Frame 067018/0603 →
Continuity (6)
Continuation 16904824 · Jun 18, 2020
Continuation 15811040 · Nov 13, 2017
Continuation 14418392
Provisional Application 61835825 · Jun 17, 2013
Provisional Application 61677414 · Jul 30, 2012
Related Publication 20240316204A1 · Sep 26, 2024
References Cited (60)
US 4663161A · Mannino et al. · 1987 [cited by applicant]
US 5554382A · Castor · 1996 [cited by applicant]
US 6660504B2 · Yamane et al. · 2003 [cited by applicant]
US 6663885B1 · Hager et al. · 2003 [cited by applicant]
US 8642073B2 · Mannino et al. · 2014 [cited by applicant]
US 9370572B2 · Mannino · 2016 [cited by examiner]
US 9775907B2 · Mannino · 2017 [cited by examiner]
US 10716860B2 · Mannino · 2020 [cited by examiner]
US 11964019B2 · Mannino et al. · 2024 [cited by applicant]
US 20020106744A1 · Yamane et al. · 2002 [cited by applicant]
US 20030054027A1 · Unger · 2003 [cited by applicant]
US 20030219473A1 · Zarif et al. · 2003 [cited by applicant]
US 20040120997A1 · Panzner et al. · 2004 [cited by applicant]
US 20040146551A1 · Mannino et al. · 2004 [cited by applicant]
US 20050008686A1 · Mannino et al. · 2005 [cited by applicant]
US 20050013854A1 · Mannino et al. · 2005 [cited by applicant]
US 20050013855A1 · Gould-Fogerite et al. · 2005 [cited by applicant]
US 20050118241A1 · Landschaft · 2005 [cited by applicant]
US 20100239521A1 · Mozafari · 2010 [cited by applicant]
US 20110256214A1 · Martin et al. · 2011 [cited by applicant]
US 20150140074A1 · Mannino et al. · 2015 [cited by applicant]
US 20150147380A1 · Mannino et al. · 2015 [cited by applicant]
US 20150297725A1 · Mannino et al. · 2015 [cited by applicant]
US 20180185491A1 · Mannino et al. · 2018 [cited by applicant]
US 20240423916A1 · Mannino et al. · 2024 [cited by applicant]
EP 1223222A1 · 2002 [cited by applicant]
EP 2689775A1 · 2014 [cited by applicant]
JP H0550062A · 1993 [cited by applicant]
JP 2005112731A · 2005 [cited by applicant]
JP 2010235520A · 2010 [cited by applicant]
WO WO91002517A1 · 1991 [cited by applicant]
WO WO9311777A1 · 1993 [cited by applicant]
WO WO9412155A1 · 1994 [cited by applicant]
WO WO9412156A1 · 1994 [cited by applicant]
WO WO96025147A1 · 1996 [cited by applicant]
WO WO02085337A1 · 2002 [cited by applicant]
WO WO03082209A2 · 2003 [cited by applicant]
WO WO2004012709A1 · 2004 [cited by applicant]
WO WO2004037271A1 · 2004 [cited by applicant]
WO WO2004041247A2 · 2004 [cited by applicant]
WO WO2004064805A1 · 2004 [cited by applicant]
WO WO2004091578A2 · 2004 [cited by applicant]
WO WO2007117509A2 · 2007 [cited by applicant]
WO WO2010091090A1 · 2010 [cited by applicant]
WO WO2012151517A1 · 2012 [cited by examiner]
WO WO2014022414A1 · 2014 [cited by applicant]
“Handbook of Pharmaceutical Excipients, 5th edition (2006):http:/www.gmpua.com/RD/RD/HandbookPharmaceutical%20Excipients.pdf.” [cited by applicant]
Xu et al., “Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated With Amphotericin B Plus Flucytosine Alone or in Combination With Fluco… [cited by applicant]
BioDelivery Sciences, “New BioGeode(TM) Cochleates Could Make Healthy Nutrients More Available In Processed Foods”, Sep. 30, 2003, 2 pages. [cited by applicant]
Chinese Office Action and Search Report dated Feb. 21, 2017 for Chinese Patent Application No. 201380051033.2, 24 pages (including English translation). [cited by applicant]
Duzgunes et al. (1981). “Calcium- and Magnesium-Induced Fusion of Mixed Phosphatidylserine/Phosphatidylcholine Vesicles: Effect of IOn Binding.” The Journal of Membrane Biology, 59:115-125. [cited by applicant]
Extended EP Search Report dated Feb. 10, 2016 from EP Application No. 13826076.5, pp. 1-9. [cited by applicant]
First Examination Report dated Nov. 21, 2019 for Indian Application No. 1083/CHENP/2015, 8 pages. [cited by applicant]
Google scholar search Jan. 25, 2022 phosphatidylserine cochleate drug (Year: 2022). [cited by applicant]
Google scholar search Jan. 25, 2022 phosphatidylserine cochleate drug nnannino (Year: 2022). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2013/052756 dated Dec. 6, 2013. [cited by applicant]
Japanese Office Action dated May 23, 2017 for Japanese Application No. 2015-525517, 10 pages (including English translation). [cited by applicant]
Maiskiy V.V. “Elementary Pharmacology”, 2009, p. 422. [cited by applicant]
Non-Final Office Action from U.S. Appl. No. 14/418,392 mailed Apr. 21, 2016, pp. 1-26. [cited by applicant]
Zayas et al., “Pilot Scale Production of the Vaccine Adjuvant Proteoliposome Derived Cochleates (AFC01) from Neisseria Meningitidis Serogroup B,” BMC Immunology 2013, 14(Suppl 1):54, pp. 1-5. [cited by applicant]